{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05877885",
            "orgStudyIdInfo": {
                "id": "22-09025304"
            },
            "secondaryIdInfos": [
                {
                    "id": "K23MH129882",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/K23MH129882"
                }
            ],
            "organization": {
                "fullName": "Weill Medical College of Cornell University",
                "class": "OTHER"
            },
            "briefTitle": "Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics",
            "officialTitle": "Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics",
            "therapeuticArea": [
                "Other"
            ],
            "study": "targeting-network-dysfunction-in-apathy-of-late-life-depression-using-digital-therapeutics"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-17",
            "studyFirstSubmitQcDate": "2023-05-17",
            "studyFirstPostDateStruct": {
                "date": "2023-05-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Weill Medical College of Cornell University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute of Mental Health (NIMH)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this randomized controlled trial is to evaluate the potential of a customized digital cognitive training intervention to target aspects of brain function in apathy of late-life depression and reduce symptoms of apathy and related cognitive and behavioral deficits. The investigators hypothesize that 4 weeks of a customized digital cognitive training program will lead to changes in brain connectivity, apathy severity, and cognitive control performance."
        },
        "conditionsModule": {
            "conditions": [
                "Major Depressive Disorder",
                "Apathy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 84,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Targeted Cognitive Training Intervention",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Behavioral: Targeted Cognitive Training Intervention"
                    ]
                },
                {
                    "label": "General Cognitive Training Intervention",
                    "type": "ACTIVE_COMPARATOR",
                    "interventionNames": [
                        "Behavioral: General Cognitive Training Intervention"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "Targeted Cognitive Training Intervention",
                    "description": "In this intervention, participants will complete 25-30 minutes of cognitive training per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform, and includes tasks that emphasize training of sustained attention, salience detection, and dimensions of cognitive control. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.",
                    "armGroupLabels": [
                        "Targeted Cognitive Training Intervention"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "General Cognitive Training Intervention",
                    "description": "In this intervention, participants will complete 25-30 minutes of cognitive activities per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform. The intervention protocol will include computerized cognitive activities designed to provide general cognitive stimulation. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.",
                    "armGroupLabels": [
                        "General Cognitive Training Intervention"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Resting State Functional Connectivity among the Salience, Executive Control, and Reward Networks",
                    "description": "Calculated from resting state fMRI scan. Validation of target engagement.",
                    "timeFrame": "Baseline and Post-treatment (Week 4)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in Apathy Evaluation Scale (AES) score",
                    "description": "The 18-item clinician-rated version of the Apathy Evaluation Scale (AES) will be used to measure apathy severity. Scores range from 18 (no apathy) to 72 (severe apathy).",
                    "timeFrame": "Baseline, Mid-treatment (Week 2), and Post-treatment (Week 4)"
                },
                {
                    "measure": "Change in Stroop Interference score",
                    "description": "Stroop interference will be calculated from the computerized Stroop Task to measure cognitive control.",
                    "timeFrame": "Baseline, Mid-treatment (Week 2), and Post-treatment (Week 4)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 60+ years\n2. Diagnosis of unipolar major depressive disorder without psychotic features, as assessed by the Structured Clinical Interview for DSM-5 (SCID)\n3. Montgomery-\u00c5sberg Depression Rating Scale (MADRS) score \\> or = 16.\n4. Clinically significant apathy, determined by the Clinician-rated Apathy Evaluation Scale (C-AES \\> or = to 37)\n5. Off antidepressants or on a stable dose of an antidepressant for 8 weeks and do not intend to change the dose in the next 5 weeks.\n6. On a stable dose of other psychotropic medications, deemed by the investigator to be associated with brain networks of interest, for at least 8 weeks.\n7. Capacity to provide written consent for research assessment and treatment\n8. Ability to follow written and verbal instructions (English) as assessed by the PI and/or study staff.\n9. DRS total score \\> 129 or DRS scaled score of 5 based on age and education-adjusted normative data49\n10. Eligible to undergo MRI\n11. Access to a computer or tablet with Wifi capabilities\n12. Able to comply with all testing and study requirements and willingness to participate in the full study duration.\n\nExclusion Criteria:\n\n1. History or presence of psychiatric diagnoses other than major depressive disorder without psychotic features, persistent depressive disorder, generalized anxiety disorder, social anxiety disorder, or specific phobia\n2. Use of cholinesterase inhibitors or psychoactive drugs other than antidepressants or benzodiazepines, including antipsychotics, that in the opinion of the Investigator may confound study data/assessments.\n3. Presence or history of significant neurologic or neurodegenerative disorder (e.g., Alzheimer's disease and other dementias, amnestic Mild Cognitive Impairment, history of stroke, Multiple Sclerosis, Parkinson's disease, epilepsy).\n4. Any other acute medical condition (e.g., cardiac, renal, or respiratory failure; severe chronic obstructive pulmonary disease; metastatic cancer; or debilitated states or less common medical illnesses) that may influence brain systems of interest or interfere with participation or interpretation of the study results.\n5. Participant is currently considered at risk for attempting suicide by the Investigator, has made a suicide attempt within the past year, or is currently demonstrating active suicidal ideation or self-injurious behavior.\n6. Electroconvulsive therapy within the past 12 months\n7. Recent history (within 6 months prior to screening/baseline) of Substance Use Disorder.\n8. Participant is currently enrolled in ongoing concurrent cognitive rehabilitation (note that if a subject is enrolled in psychotherapy, this will not be grounds for exclusion)\n9. Claustrophobia\n10. Color Blindness\n11. Sensory or physical impairment that would preclude cognitive testing or participation in the intervention (e.g., upper limb paralysis) as reported by the participant or observed by the Investigator.\n12. Travelling consecutively for 2+ weeks during the study period to a location that will preclude timely collection of post-treatment MRI data.\n13. Contraindications to MRI scanning including cardiac pacemaker, heart valve replacement, vascular stent, cochlear implant, any other metallic biomedical implant contraindicating to MRI.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "60 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lauren Oberlin, PhD",
                    "role": "CONTACT",
                    "phone": "(646) 289-5204",
                    "phoneExt": "707",
                    "email": "leo4001@med.cornell.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Lauren Oberlin, PhD",
                    "affiliation": "Weill Medical College of Cornell University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Lauren Elizabeth Oberlin",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lauren E Oberlin, PhD",
                            "role": "CONTACT",
                            "phone": "646-289-5204",
                            "phoneExt": "707",
                            "email": "leo4001@med.cornell.edu"
                        },
                        {
                            "name": "Lauren Oberlin, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Weill Cornell Medicine Institute of Geriatric Psychiatry",
                    "city": "White Plains",
                    "state": "New York",
                    "zip": "10605",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lauren E Oberlin, PhD",
                            "role": "CONTACT",
                            "phone": "646-289-5204",
                            "phoneExt": "707",
                            "email": "leo4001@med.cornell.edu"
                        },
                        {
                            "name": "Lauren Oberlin, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.03399,
                        "lon": -73.76291
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The data that will be shared includes all of the individual participant data collected during the trial, after deidentification.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "Beginning 3 months following publication of primary outcomes, ending 5 years following publication of primary outcomes.",
            "accessCriteria": "Data will be made available to researchers who provide a methodologically sound proposal, to achieve the aims in the approved proposal. Proposals should be directed to the study PI, Lauren Oberlin, at leo4001@med.cornell.edu."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003866",
                    "term": "Depressive Disorder"
                },
                {
                    "id": "D000003865",
                    "term": "Depressive Disorder, Major"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019964",
                    "term": "Mood Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7058",
                    "name": "Depression",
                    "relevance": "LOW"
                },
                {
                    "id": "M7061",
                    "name": "Depressive Disorder",
                    "asFound": "Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7060",
                    "name": "Depressive Disorder, Major",
                    "asFound": "Major Depressive Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21835",
                    "name": "Mood Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M6263",
                    "name": "Coal Tar",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}